Tag Archive for: POLB 001

Poolbeg Pharma – POLB 001 LPS Challenge Trial Data to be Presented at IUIS

/in

POLB 001 – a potential blockbuster immunomodulator 16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International […]

Read more

Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent

/in

Key highlights ·      Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia ·      Allows for use in combination with an antiviral agent ·      Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline   8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’),  a leading infectious disease focused biopharmaceutical company, announces that […]

Read more

Poolbeg Pharma: Positive Results from POLB 001 LPS Human Challenge Trial

/in

Strong potential for POLB 001 to be a blockbuster treatment for severe influenza Key Highlights ·      POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines ·      POLB 001 treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo ·    Trial results demonstrate expected utility in severe influenza […]

Read more

Poolbeg announces strategic expansion of POLB 001 into oncology

/in

Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights ·      Newly filed patent application to protect use of POLB 001 for new oncology indication ·      Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory […]

Read more

Positive Initial Data Analysis in POLB 001 LPS Challenge Trial

/in

Early data read out indicates a successful LPS human challenge trial Key Highlights ·      POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo ·      A clear dose-response relationship was demonstrated                                                                 ·      Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported ·      Full […]

Read more